CD20 / MS4A1 Antibody ( FITC )

CD20 / MS4A1 Antibody Datasheet

CD20 / MS4A1 Antibody Product Information

• Immunogen: Human CD20 Transfected CHO Cells
• Reagents: FITC-conjugated rabbit monoclonal antibody
• Clone ID: 001
• Ig Type: Rabbit IgG
• Concentration: 10 μl/Test, 0.1 mg/ml
• Formulation: Aqueous solution containing 0.5% BSA and 0.09% sodium azide
• Preparation: This antibody was obtained from a rabbit immunized with purified, Human CD20 Transfected CHO Cells and conjugated with FITC under optimum conditions, the unreacted FITC was removed.

CD20 / MS4A1 Antibody Usage Guide

• Specificity: Human CD20 / MS4A1
• Flow Cytometry: Flow cytometric analysis of anti-CD20 reactivity on peripheral blood lymphocytes.
  

  Profile of anti-CD20 reactivity on peripheral blood lymphocytes analyzed by flow cytometry.

  Flow cytometry was performed on a BD FACSCalibur flow cytometry system

  Please refer to www.sinobiological.com/Flow-Cytometry-FACS-Protocols-a-750.html for technical protocols.

• Storage: This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
  Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

CD20 / MS4A1 Antibody Background

B-lymphocyte antigen CD20, also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is a multi-pass membrane protein which belongs to theMS4A family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. CD20 / MS4A1 is expressed on all stages of B cell development except the first and last. CD20 / MS4A1 is present from pre-pre B cells through memory cells, but not on either pro-B cells or plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.

References

1. Tedder TF. et al.,1988, Proc Natl Acad Sci. 85 (1): 208-12.
2. Cragg MS. et al., 2005, Curr Dir Autoimmun. 8: 140-74.
3. Fang D. et al., 2005, Cancer Res. 65 (20): 9328-37.
4. Teeling JL. et al., 2006, J Immunol. 177: 362-371.